Dostarlimab A new hope for endometrial cancer patients in Pakistan
Endometrial cancer (EC) is the most common gynaecological cancer in Pakistan, with an estimated incidence of 7.4 per 100,000 women [1]. It is a disease where cancer cells grow in the lining of the uterus (endometrium). EC can be classified into two types based on the genetic features of the cancer...
Saved in:
| Main Author: | Maliha Khan |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Pakistan Medical Association
2024-09-01
|
| Series: | Journal of the Pakistan Medical Association |
| Subjects: | |
| Online Access: | https://jpma.org.pk/index.php/public_html/article/view/10945 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pseudoprogression and improvement of quality of life in a patient with advanced endometrial cancer treated with immunotherapy: a case report
by: Valentina Tuninetti, et al.
Published: (2025-06-01) -
Successful Dostarlimab Rechallenge Following Pembrolizumab‐Induced Autoimmune Hemolytic Anemia: A Case Report
by: Zaid Khamis, et al.
Published: (2025-08-01) -
Pharmacology of Dostarlimab: A Review
by: Arnab Roy, et al.
Published: (2022-09-01) -
The frontiers in gynecologic cancer management: Exploring the new hope to manage women with endometrial cancer by immunochemotherapy
by: Peng-Hui Wang, et al.
Published: (2025-05-01) -
Outcomes for Dostarlimab and Real-World Treatments in Post-platinum Patients With Advanced/Recurrent Endometrial Cancer: The GARNET Trial Versus a US Electronic Health Record-Based External Control Arm
by: Scott Goulden, et al.
Published: (2023-09-01)